Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781612 · ClinicalTrials.gov registry record · Phase 2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
A Phase 2 study of Neoplasm Metastasis, sponsored by Genentech.
- Active
- Registry status
- Phase 2
- Development phase
- 720
- Enrollment target
- 20
- Study locations
NCT00781612 is a Phase 2 study of Neoplasm Metastasis that is active but no longer recruiting, run by Genentech. The registered enrollment target is 720 participants, above the 398-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (81% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00781612, a Phase 2 study of Neoplasm Metastasis, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 720 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Pertuzumab
- DRUG Trastuzumab Emtansine
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Can Care Assoc Med Group Inc - Redondo Beach
- Univ of Calif, San Francisco - San Francisco
- Central Coast Medical Oncology - San Luis Obispo
- UCLA Oncology Office - Santa Monica
- Stanford Cancer Institute - Stanford
- Kaiser Permanente - Walnut Creek - Walnut Creek
Florida
- Florida Cancer Specialists - Fort Myers
- Memorial Cancer Institute at Memorial West - Pembroke Pines
- Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building) - St. Petersburg
- Florida Cancer Specialists - Tampa (Dr. MLK Blvd) - Tampa
Colorado
- Univ of Colorado Canc Ctr - Aurora
- University of Colorado - Aurora
- Rocky Mountain Cancer Center - Denver - Denver
Illinois
- Loyola University Med Center - Maywood
- Illinois Cancer Care - Peoria
Delaware
- Christina Care Institutional Review Board - Newark
Georgia
- Northwest Georgia Oncology Centers PC - Marietta - Marietta
Idaho
- Kootenai Cancer Center - Post Falls
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2008-10-16 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781612
The ClinicalTrials.gov registry entry for NCT00781612 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 398-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (81% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasm Metastasis appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT00781612 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00781612 about?
NCT00781612 is a clinical study titled "A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies". This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the ...
What is the current status of trial NCT00781612?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 720 participants. The study started on 2008-10-16. Estimated completion is 2030-04-30.
What conditions does trial NCT00781612 study?
This clinical trial studies the following conditions: Neoplasm Metastasis.
What interventions are being tested in trial NCT00781612?
The interventions under investigation include: Trastuzumab (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Pertuzumab (DRUG), Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT00781612?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00781612 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
-
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
COMPLETED · Phase 2
-
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.